-
2022-502185-24-00
5
Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-517561-16-00
4
non-small cell lung cancer
-
2025-523704-77-00
4
Geographic atrophy secondary to age-related macular degeneration
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2022-501095-25-01
5
2024-11-04
Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to < 18 Y
-
2023-509469-19-00
11
2024-04-17
Non-Infectious Uveitis affecting the posterior segment
-
2022-501478-21-00
5
2024-03-15
Atopic Dermatitis
Eczema
-
2025-523658-15-00
5
2026-04-10
Obesity
-
2025-522642-44-00
4
2026-03-18
CHRONIC SPONTANEOUS URTICARIA
-
2024-520384-14-00
4
2025-11-20
Centre-involved diabetic macular edema
-
2025-521744-37-00
5
2025-11-17
Mild to moderate major depressive disorder
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-519945-31-00
5
2025-08-21
Type 1 Diabetes
-
2024-517545-13-00
11
2025-06-04
Neovascular Age-Related Macular Degeneration
-
2023-509547-27-00
5
2025-05-22
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2023-507878-41-00
4
2025-04-25
Acute myeloid leukemia
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2024-512798-29-00
5
2025-01-07
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-509292-17-00
4
2024-11-08
primary high-risk lobular breast cancer